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The contribution of B cells to the pathology of Omenn syndrome and leaky severe combined 
immunodeficiency (SCID) has not been previously investigated. We have studied a mut/mut 
mouse model of leaky SCID with a homozygous Rag1 S723C mutation that impairs, but does 
not abrogate, V(D)J recombination activity. In spite of a severe block at the pro–B cell stage and 
profound B cell lymphopenia, significant serum levels of immunoglobulin (Ig) G, IgM, IgA, and 
IgE and a high proportion of Ig-secreting cells were detected in mut/mut mice. Antibody  
responses to trinitrophenyl (TNP)-Ficoll and production of high-affinity antibodies to TNP–
keyhole limpet hemocyanin were severely impaired, even after adoptive transfer of wild-type 
CD4+ T cells. Mut/mut mice produced high amounts of low-affinity self-reactive antibodies and 
showed significant lymphocytic infiltrates in peripheral tissues. Autoantibody production was 
associated with impaired receptor editing and increased serum B cell–activating factor (BAFF) 
concentrations. Autoantibodies and elevated BAFF levels were also identified in patients with 
Omenn syndrome and leaky SCID as a result of hypomorphic RAG mutations. These data indicate 
that the stochastic generation of an autoreactive B cell repertoire, which is associated with 
defects in central and peripheral checkpoints  
of B cell tolerance, is an important, previously 
unrecognized, aspect of immunodeficiencies 
associated with hypomorphic RAG mutations.
© 2010 Walter et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http://www.rupress.org/terms). After six months it is available 
under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 
Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Khiong et al., 2007; Giblin et al., 2009). Investigation of the 
molecular and cellular basis of immune dysregulation in these 
models and in patients has been largely restricted to the analy-
sis of T cell development, function, and tolerance (Cavadini 
et al., 2005; Marrella et al., 2007; Khiong et al., 2007; Giblin 
et al., 2009; Poliani et al., 2009). However, the possible contri-
bution of B lymphocytes to the immunopathology of Omenn 
syndrome and leaky SCID has been neglected.
We hypothesized that hypomorphic RAG mutations may 
result in the generation of a residual number of peripheral 
B cells that contain self-reactive BCR specificities as a result 
of defects of receptor editing. We also hypothesized that the 
B cell lymphopenic environment secondary to hypomorphic 
RAG mutations may result in increased BAFF levels that can 
impact on competition for survival signals in the periphery 
and, thus, rescue self-reactive B cells. By studying a homozy-
gous Rag1S723C (mut/mut) mouse model of leaky SCID, as well 
as patients with RAG-dependent Omenn syndrome and leaky 
SCID, we now report for the first time that defects in the 
mechanisms of B cell tolerance and altered distribution and 
maturation of peripheral B cells are integral components of 
the immunopathology of these disorders.
RESULTS
Mut/mut mice have a severe but incomplete block  
in B cell development
Flow cytometric analysis revealed a severe but incomplete de-
velopmental block at the pro–B cell stage in the bone marrow 
of 8-wk-old mut/mut mice, as indicated by the increased pro-
portion of B220+ IgM CD43+ pro–B cells and decreased 
proportion of B220+ IgM CD43 pre–B cells. Virtually no 
immature and mature recirculating B220+ IgM+ B cells were 
present (Fig. 1 A). Furthermore, both the proportion and the 
absolute number of splenic transitional (T) 1 to T3 cells, Fo1 
and Fo2 cells, and MZ precursors and mature MZ B cells were 
dramatically decreased in mut/mut mice; however, they showed 
accumulation of B220int CD93hi cells (Fig. 1 B). CD93 (AA4.1) 
is a marker of immature B cells that is reexpressed during ter-
minal B cell differentiation from pre-plasmablasts (PBs [pPBs]) 
to plasma cells (PCs; Chevrier et al., 2009). The B220int CD93hi 
B cell population in the spleen of mut/mut mice included both 
CD138 pPB and CD138+ PC. Furthermore, the proportion 
of switched B cells that expressed surface IgG1 or IgG2a was 
also significantly increased (Fig. 1 B). To better define the mat-
uration stage of B220+ cells in the spleen of mut/mut mice, we 
stained them for BAFF-R, which is not expressed in early B 
cell progenitors. We found that mut/mut splenic B220+ cells 
expressed BAFF-R at levels comparable to B220+ cells from 
wild-type mice (unpublished data), confirming that most 
splenic B220+ cells were mature B lymphocytes. Immunoscope 
profiling of negatively selected B cell–enriched splenocytes 
demonstrated a highly restricted pattern of the peripheral B cell 
repertoire in mut/mut mice as compared with wild-type con-
trols (Fig. S1). Immunofluorescence staining of the spleen from 
mut/mut mice revealed absence of follicles and germinal centers 
but accumulation of PC in the extrafollicular areas (Fig. S2). 
B cells are generated in the bone marrow, where stochastic 
rearrangements of the variable (V), diversity (D), and joining 
(J) elements within the Ig heavy and light chains lead to de-
velopment of the primary B cell repertoire (Alt and Baltimore, 
1982). This process, known as V(D)J recombination, strictly 
requires expression of the lymphoid-specific RAG1 and RAG2 
genes (Schatz et al., 1989; Oettinger et al., 1990). A large pro-
portion of immature B cells that are produced in the bone mar-
row express a BCR that recognizes self antigens (Wardemann 
et al., 2003). Security checkpoints in the bone marrow and in 
the periphery allow purging of self-reactive B cells. In partic-
ular, BCR cross-linking by self-antigens arrests B cell devel-
opment and promotes persistent expression of RAG gene and 
Ig light chain gene rearrangement (Gay et al., 1993; Tiegs et al., 
1993; Radic et al., 1993). As a result of this process, also 
known as receptor editing, self-reactive receptors are replaced 
by a non–self-reactive repertoire. In addition, immature B cells 
that bind self-antigens with high affinity are rapidly deleted 
in the bone marrow (Halverson et al., 2004). Persistent and 
low-affinity interaction of B cells with self antigens induces a 
state of unresponsiveness. These anergic self-reactive B cells 
can be exported to the periphery, where a secondary check-
point of B cell tolerance takes place (Melchers, 2006; Merrell 
et al., 2006; Miller et al., 2006). Differentiation of transitional to 
mature Fo (follicular) or marginal zone (MZ) B cells and de-
velopment of B-1 cells are dictated by the strength of BCR 
signaling and by response to other survival factors that shape the 
preimmune B cell repertoire (Khan et al., 1995; Hayakawa et al., 
1999; Cariappa et al., 2001; Pillai et al., 2004; Stadanlick and 
Cancro, 2008). Among survival factors that may modulate 
peripheral B cell fate, a key role is played by B cell–activating 
factor (BAFF). Anergic self-reactive B cells express lower 
amounts of BAFF receptor (BAFF-R) and, hence, are at a 
disadvantage to non–self-reactive B cells in their response to 
BAFF (Lesley et al., 2004). Therefore, at physiological con-
centrations BAFF contributes to purging of self-reactive B cells 
in the periphery.
RAG mutations in humans are associated with heteroge-
neous clinical phenotypes. Although complete lack of RAG 
activity leads to an SCID phenotype with absence of mature 
T and B cells (T B SCID; Schwarz et al., 1996), hypomorphic 
RAG mutations allow limited generation and export of T cells, 
and sometimes B cells, to the periphery (Villa et al., 2001). 
This leaky SCID condition may associate with severe mani-
festations of immune dysregulation, as exemplified by Omenn 
syndrome, which is characterized by erythroderma, lymphade-
nopathy, and inflammatory gut disease associated with tissue-
infiltrating T lymphocytes (Villa et al., 1998). A novel and milder 
phenotype of leaky SCID, characterized by granuloma for-
mation, Epstein-Barr Virus-related lymphoma and survival 
into late childhood, has been recently described (Schuetz et al., 
2008). In the past, investigation of the immunopathology of 
Omenn syndrome and leaky SCID has been hampered by the 
lack of adequate animal models. Three mouse models carry-
ing hypomorphic Rag mutations have been described that 
mimic Omenn syndrome or leaky SCID (Marrella et al., 2007; 
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the spleen of mut/mut mice than in 
wild-type mice (IgM ISC, P < 0.05; 
IgG1, P < 0.05; IgA, P < 0.005; Fig. 2 B). 
Molecular markers can be used to 
track maturation of B cells in the pe-
riphery. In particular, Ig heavy chain 
class switch recombination is marked 
by expression of post-switch transcripts, 
whereas differentiation from B220int 
CD93hi CD138 pPB to B220int 
CD93hi CD138+ ISCs is accompanied by progressive decrease 
of Pax5 and Blc6 expression and up-regulation of the Blimp-1, 
Xbp-1, and Irf-4 transcription factors (Muramatsu et al., 2000; 
Reimold et al., 2001; Chevrier et al., 2009). In keeping with 
a high proportion of B220int CD93hi cells, many of which co-
express CD138 and have a large size, we found that splenic B 
cells from naive mut/mut mice express high levels of Xbp-1 
and of I-C1 switch transcripts (Fig. 2 C).
Antibody responses and dysregulation of B cell–mediated 
immunity in mut/mut mice
Next, we analyzed the ability of mut/mut mice to mount anti-
body responses to T-independent (TI) and T-dependent (TD) 
Consistent with the relative expansion of terminally differenti-
ated B cells, Ig serum levels were largely preserved in mut/mut 
mice (Fig. 2 A). In particular, serum levels of IgG1, IgG2a, and 
IgE were higher in 8-wk-old mut/mut mice than in age-
matched controls. IgA serum levels were initially low but nor-
malized by 16 wk of age (unpublished data). In keeping with 
the restricted diversity of peripheral B cell repertoire, an oligo-
clonal profile of Igs was demonstrated by serum electrophoresis 
and immunofixation in 8-wk-old mut/mut mice (Fig. S3 A).
To confirm that the splenic B cell compartment of mut/
mut mice is skewed to Ig-secreting cells (ISCs), we performed 
ELISPOT assays in 12-wk-old mice and found a higher pro-
portion of IgM-, IgG1-, IgG2a-, and IgA-secreting cells in 
Figure 1. Rag1S723C mut/mut mice have a 
severe but incomplete block in B cell de-
velopment. (A) Distribution of B lymphocyte 
subsets in the bone marrow. Left: representa-
tive FACS analysis of bone marrow cells from 
indicated 8-wk-old mice labeled with B220 
and IgM antibodies, and histograms of CD43 
expression gated on B220+ IgM subset. Right: 
Percentage (mean and SD) of indicated bone 
marrow B cell subsets in Rag1S723C (mut/mut) 
and wild type (+/+) mice. Imm, immature B cells; 
Mat, mature recirculating B cells. P-values  
(**, P < 0.01; ****, P < 0.001) were determined 
by the Mann-Whitney U test. Seven mice per 
group were analyzed in three experiments.  
(B) Distribution of B lymphocyte subsets in 
the spleen. Top: strategy for gating on transi-
tional (T1-3), MZ precursor (MZP), Fo type I 
and II (Fo1-2), MZ B cells, CD93hi B220int 
CD138 pPB, and CD93hi B220int CD138+ PC 
subpopulations of splenic B cells after excluding 
DAPI+, Dump+(CD11c, CD11b, and Gr-1), and 
B220 cells. One representative example is 
shown for both wild-type (+/+) and mut/mut 
mice out of three wild-type (+/+) and seven 
mut/mut 8-wk-old mice that were analyzed in 
two experiments. Bottom: distribution (per-
centage of B220+ splenocytes) and absolute 
numbers (mean ± SD) of splenic B cell sub-
sets, defined as in A, in 8-wk-old wild-type 
(+/+, n = 3) and mut/mut (n = 7) mice. 
sIgG1/sIgG2a, lymphocytes expressing  
surface IgG1 or surface IgG2a. P-values  
(**, P < 0.01; ****, P < 0.001) were determined 
by the Mann-Whitney U test.
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injected i.v. with 3 × 106 purified splenic CD4+ T cells from 
either wild-type or mut/mut mice, before immunization with 
TNP-KLH. To control whether the amount of adoptively 
transferred wild-type CD4+ T cells was sufficient to support 
specific antibody production and affinity maturation, the same 
amount of CD4+ T cells were transfused into Zap70/ mice, 
which lack peripheral T cells but have an intact and diversi-
fied repertoire of B lymphocytes (Negishi et al., 1995). As 
shown in Fig. 3 (E and F), adoptive transfer of wild-type CD4+ 
splenic T cells allowed production of a robust high-affinity 
TNP-specific antibody response in Zap70/ mice, but not 
in mut/mut mice, upon immunization with TNP-KLH. Alto-
gether, these data indicate that naive mut/mut mice sponta-
neously produce higher amounts of low-affinity antibodies 
but fail to mount robust antibody responses upon challenge 
with either TI or TD antigens, and that the severe impair-
ment of high-affinity antibody response to TD antigens is not 
simply a result of lack of adequate helper T cell activity.
Because elevated levels of Igs (and especially IgG2a) and 
spontaneous production of low-affinity antibodies are often 
associated with the presence of self-reactive specificities (Kang 
et al., 1988), we screened mut/mut mice for the presence of 
autoantibodies. Titers of anti–single-stranded DNA (ssDNA) 
and anti-chromatin (DNA/histone) antibodies were signifi-
cantly increased in 8- and 16-wk-old mut/mut mice, compared 
with age-matched wild-type mice, but normalized by 6–8 mo 
antigens. At day 14 after immunization with the TI antigen 
TNP-Ficoll, production of both IgM and IgG3 anti-TNP anti-
bodies was reduced in mut/mut mice as compared with wild-
type controls (P < 0.0001 and P < 0.005 for IgM and IgG3 
TNP-specific responses, respectively; Fig. 3, A and B). How-
ever, higher levels of TNP-binding IgM antibodies were de-
tected in nonimmunized mut/mut mice (P < 0.05; Fig. 3 A). 
Naive mut/mut mice also had higher levels of low-affinity TNP-
reactive IgG antibodies than wild-type mice (P < 0.0001; 
Fig. 3 C), but the TNP-specific total IgG response after 
primary and secondary immunization with the TD antigen 
TNP-KLH was blunted (Fig. 3 C). Furthermore, levels of 
high-affinity TNP-specific IgG antibodies after primary immu-
nization with TNP-KLH were significantly lower in mut/mut 
mice versus controls (P < 0.0001; Fig. 3 D), and only a mod-
est increase was observed after secondary immunization, as 
compared with a 30-fold increase in wild-type mice (Fig. 3 D, 
mut/mut vs. wild-type mice; P < 0.0001). These data indicate 
a severe defect of affinity maturation in mut/mut mice.
It has been previously shown that mut/mut mice have an 
abnormal T cell compartment, with reduced number of 
peripheral T cells, most of which express activation markers 
(Giblin et al., 2009). To evaluate whether lack of robust and 
high-affinity responses to TD antigens in mut/mut mice might 
simply reflect lack of adequate helper T cell activity, we per-
formed adoptive transfer experiments. Mut/mut mice were 
Figure 2. Ig serum levels and analysis of splenic ISCs in mut/mut mice. (A) Sera from 8-wk-old naive wild-type (n = 11–13) and Rag1S732C mut/mut 
(n = 11–14) mice were collected and IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, and IgE concentrations were determined by ELISA in three independent experi-
ments, and three to five mice for each strain (+/+ or mut/mut) were included in each experiment. Horizontal bars identify mean values. P-values  
(*, P < 0.05; ****, P < 0.001) were determined by a Student’s t test for unpaired data. (B) The proportion of ISCs among the B cell–enriched fraction of sple-
nocytes of 12-wk-old wild-type and Rag1 mut/mut mice was analyzed by ELISPOT assay for IgM (+/+ n = 7; mut/mut n = 12), IgG1 (+/+ n = 7; mut/mut  
n = 15), IgG2a (+/+ n = 5; mut/mut n = 11), and IgA (+/+ n = 6; mut/mut n = 10). Splenocytes were enriched for B cells by negative selection. Spots were 
counted by an ELISPOT Reader using a size range of 0.005–1 mm. Results are expressed as mean ± SD. Horizontal bars identify mean values. P-values  
(*, P < 0.05; ***, P < 0.005) were determined by the Mann-Whitney U test. Three ELISPOT experiments were performed that included both +/+ and mut/mut 
B cell–enriched splenocytes. The enriched splenic B cell preparation from one Aicda/ mouse was tested in parallel in each experiment to confirm specific-
ity of detection of switched isotypes. (C) RT-PCR amplification of I-C1 post-switch transcripts and of xbp1 transcripts from cDNA prepared from B cell–
enriched (CD90 negative) splenocytes from wild-type (+/+, n = 3) and mut/mut (n = 3) mice. Expression of mb1 transcript was analyzed as internal control. 
One representative example of three replicates of the RT-PCR reaction is shown. The molecular size of amplified cDNAs is indicated in parentheses.
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Immunohistochemical analysis showed that the majority 
of mut/mut mice had prominent inflammatory infiltrates, which 
included T and B lymphocytes, in various target organs (Fig. S7 
and Table S1). However, this immunopathology was not as-
sociated with reduced survival or weight loss in the vast 
majority of mut/mut mice, and only 4% of them developed 
features of Omenn syndrome (hair loss and severe colitis). 
Altogether, these data indicate that homozygosity for a hypo-
morphic Rag1 mutation in mut/mut mice is associated with 
production of broadly reactive low-affinity autoantibodies 
and inflammatory infiltrates, with potential for significant im-
munopathology in vivo.
Defective checkpoints of B cell tolerance in rag1 mut/mut mice
Receptor editing is the primary mechanism by which auto-
reactive B cells change their BCR specificity in the bone 
marrow. Reexpression of the RAG genes is strictly necessary 
for receptor editing to occur. We hypothesized that hypo-
morphic Rag1 mutation in mut/mut mice may impair recep-
tor editing, thus facilitating persistence of self-reactive B cells. 
The efficiency of receptor editing can be evaluated by 
measuring V-RS rearrangement (Panigrahi et al., 2008), in 
which an upstream V gene element is joined to a noncoding 
RS element located 25 kb downstream of the C element 
(Durdik et al., 1984; Daitch et al., 1992). The highest levels of 
RS rearrangement are found in bone marrow small pre–B II 
cells (Panigrahi et al., 2008), corresponding to Hardy’s classi-
fication Fraction D bone marrow cells, which also express Rag1 
and Rag2 genes (Hardy et al., 1991). To further highlight the 
importance of RS rearrangement in receptor editing and 
of age (Fig. 4, A and B). When sera from three mice with high 
concentrations of anti-ssDNA IgG were tested for the presence 
of  and  light chains, reactivity against ssDNA was detected 
only for -, but not -containing Igs (Fig. S4 A). Furthermore, 
using an immunofluorescence assay on Hep2 target cells, we 
found that 16/29 (55.2%) sera of 8–16-wk-old mut/mut mice 
contained autoantibodies with different specificities (Fig. S4 B), 
versus only 2/16 (12.5%) autoantibody-positive sera from 
age-matched wild-type controls (Fig. 4 C). The presence of 
broadly reactive autoantibodies in mut/mut mice was also 
confirmed by immunohistochemistry using a variety of tissues 
(skin, stomach, large bowel, kidney, salivary glands, and mus-
cles) from rag2/ mice as targets (Fig. S5 A and not depicted). 
We took advantage of the cohort of mut/mut mice that had 
received adoptive transfer of wild-type CD4+ T cells to assess 
whether this could modulate autoantibody production. How-
ever, no significant changes were recorded in the levels of anti-
chromatin IgG for up to 54 d after adoptive transfer (Fig. S6).
IgM and C3 deposits were demonstrated by immunofluo-
rescence in kidney sections from 8-mo-old mut/mut mice 
(Fig. S5 B) but were not associated with proteinuria. Further-
more, no proteinuria was found in a cohort of 16 mut/mut 
mice from 3 to 8 mo of age. Autoantibodies may have a different 
pathogenicity profile depending on their affinity for self anti-
gens. To assess the affinity of anti-ssDNA antibodies in mut/mut 
mice, we analyzed antigen binding at various salt concentrations 
and compared the profile to that observed in the serum of 
NZM2410 mice, a model of systemic lupus erythematosus 
with high-affinity autoantibodies. As shown in Fig. 4 D, anti-
ssDNA antibodies in mut/mut mice were of low affinity.
Figure 3. Mut/mut mice spontaneously produce low-
affinity antibodies but fail to respond to immunization 
with TI and TD antigens. Serum levels of IgM (A) and IgG3 
(B) anti-TNP antibodies were measured before (t0) and 14 d 
after (t14) immunization with the TI antigen TNP-Ficoll in  
8-wk-old wild-type (+/+, n = 4) and mut/mut mice (n = 5) 
mice. (C) Levels of total TNP-reactive serum IgG antibodies 
were analyzed before (t0) and 7 d after (t21) secondary immu-
nization with the T cell–dependent antigen TNP-KLH in wild-
type (+/+, n = 5) and mut/mut (n = 5) mice. (D) Serum levels 
of high-affinity TNP-specific IgG antibodies were analyzed  
2 wk after primary immunization (t14) and 1 wk after second-
ary immunization (t21) in wild-type (+/+, n = 5) and mut/mut 
(n = 5) mice. (E) Levels of total TNP-reactive serum IgG anti-
bodies 7 d after secondary immunization in +/+, mut/mut, 
and Zap70/ mice, with or without adoptive transfer of 
purified splenic CD4+ T cells from mut/mut or +/+ mice, as 
indicated. Five mice per group were analyzed. (F) Serum levels 
of high-affinity TNP-specific IgG antibodies were analyzed  
1 wk after secondary immunization in +/+, mut/mut, and 
Zap70/ mice with or without adoptive transfer of purified 
splenic CD4+ T cells from mut/mut or +/+ mice, as indicated. 
Five mice per group were analyzed. In all panels, results are 
expressed as mean ± SD values of OD. For each dilution of 
serum, three replicates were run in parallel. For the experiments shown in A–D, two separate sets of immunizations were performed for both TNP-Ficoll 
and TNP-KLH immunization of +/+ and mut/mut mice, and each set included two to three mice per genotype. Sera were collected at the indicated time 
points and levels of specific antibodies were measured in three independent ELISA experiments, each of which included all sera.
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Under normal circumstances, self-reactive B cells that es-
cape deletion or receptor editing in the bone marrow are 
purged at a peripheral checkpoint, where they compete with 
non–self-reactive B cells for survival signals. BAFF is a key 
factor that may modulate survival of peripheral B cells be-
yond the T1 stage of differentiation, when BAFF-R begins to 
be expressed (Hsu et al., 2002; Darce et al., 2007a,b). There 
is evidence both in mice and in humans that BAFF levels are 
regulated by the number of peripheral B cells, with higher 
levels being detected in B cell lymphopenic hosts (Cambridge 
et al., 2006; Lavie et al., 2007). Consistent with this, serum 
BAFF levels were markedly higher in mut/mut mice than in 
control mice both at 8 and 16 wk of age (Fig. 5 B). However, 
lower BAFF serum levels were detected in mut/mut mice at 
9–10 mo of age as compared with 8- or 16-wk-old mut/mut 
mice (Fig. 5 B) This decrease was inversely correlated with an 
increase in the absolute number of B220+ splenic B cells in 
9–10-mo-old versus 16-wk-old mut/mut mice (mean ± SD, 
13.0 ± 3.8 vs. 3.8 ± 1.9 × 106 cells, P = 0.0013 ; n = 5 for 
both groups) and was associated with normalization of the 
levels of anti-ssDNA and anti-chromatin antibodies (Fig. 4, 
A and B).
Increased BAFF levels and autoantibodies in patients  
with RAG-dependent immunodeficiency
The results obtained in mut/mut mice prompted us to analyze 
sera of patients with RAG-dependent immunodeficiencies for 
evidence of B cell–mediated autoimmunity. In spite of a se-
vere B cell lymphopenia, patients with leaky SCID and with 
Omenn syndrome as a result of hypomorphic RAG mutations 
often have residual Ig serum levels, and IgEs in particular are 
typically increased (Villa et al., 2001; Sobacchi et al., 2006), 
arguing for the presence of ISCs. However, humoral immu-
nity in these patients has received little attention in the litera-
ture. We have analyzed BAFF serum levels and autoantibodies 
in a cohort of patients with various forms of combined 
immunodeficiency and in 11 age-matched healthy infants. As 
shown in Fig. 6, serum BAFF levels were 10-fold higher in 
patients with RAG and Artemis deficiency than in controls 
and were also higher than in patients with X-linked SCID 
(SCIDX1), a condition characterized by lack of circulating 
T and NK lymphocytes but a normal number of B cells.
As shown in Table I, serum autoantibodies were detected 
in the majority (9 out of 14) of patients with hypomorphic 
RAG mutations leading to Omenn syndrome or leaky SCID. 
In contrast, none of the 14 patients with SCIDX1 had detectable 
autoantibodies (Omenn/leaky SCID vs. SCIDX1, P < 0.0005), 
and only 1 out of 6 control infants tested borderline positive 
(1:40) for antinuclear antibodies (ANAs). Among patients with 
hypomorphic RAG mutations, ANA (at a titer of 1:80 or 
greater) were more commonly detected and were shown to be 
of IgM isotype. We tested sera from four patients with Omenn 
syndrome caused by hypomorphic RAG mutations for oligo-
clonality by electrophoresis and immunofixation, and one such 
serum showed a restricted pattern (Fig. S3 B). These results 
demonstrate that increased autoantibody production and 
purging of self-reactive B cells, deletion of the RS element in 
mice has been found to cause persistence of autoreactive 
B cells in the periphery (Vela et al., 2008). We analyzed the 
levels of RS rearrangement in B220+ CD43 AA4.1+ IgM 
sorted Fraction D bone marrow B cells from mut/mut and 
control mice. A striking defect of RS rearrangement was ob-
served in mut/mut mice (Fig. 5 A), thus establishing that the 
Rag1 S723C mutation strongly impairs receptor editing. It 
has been shown that impairment of receptor editing in mice 
is associated with a decreased proportion of B lymphocytes 
expressing  light chains (Vela et al., 2008). This was also the 
case in mut/mut mice, in which + cells were only 0.43 ± 0.61 
(mean ± SD) % of B220hi splenic B cells, as compared with 
2.46 ± 0.42% in wild-type controls (P < 0.001, n = 5 for 
both groups).
Figure 4. Autoantibodies in mut/mut mice. (A) Serum levels of IgG 
autoantibodies to ssDNA in wild-type (+/+) and mut/mut mice at 8 wk 
(+/+, n = 9; mut/mut, n = 13), 16 wk (+/+, n = 10; mut/mut, n = 13), and 
6–8 mo (+/+, n = 6; mut/mut, n = 8) of age. P-values (***, P < 0.005) were 
determined by the Mann-Whitney U test. (B) IgG autoantibodies to chro-
matin (histone–DNA complex) in +/+ and mut/mut mice at 8 wk (+/+,  
n = 9; mut/mut, n = 14), 16 wk (+/+, n = 10; mut/mut, n = 14), and 6–8 mo 
(+/+, n = 6; mut/mut, n = 8) of age. In A and B, horizontal bars represent 
mean values. Results are expressed as ELISA units (EU), derived from serial 
dilutions of ANA-positive NZM2410 serum pool. For each serum sample, 
two replicates were run in parallel, and three experiments were per-
formed. P-values (*, P < 0.05; **, P < 0.01) were determined by the Mann-
Whitney U test. (C) Proportion of 8–16-wk-old wild-type (+/+, n = 16) 
and mut/mut mice (n = 29) whose serum contained ANAs, as measured 
using Hep2 immunofluorescence staining. The number of mice analyzed 
in each group is indicated on top of the bars. P-values (***, P = 0.005) 
were determined by the 2 test. (D) Affinity of anti-ssDNA IgG antibodies 
was measured by ELISA, using increasing salt concentrations, in the serum 
of mut/mut (n = 8) and NZM2410 (n = 7) mice. For this experiment, sera 
of mut/mut mice with high levels of anti-ssDNA IgG were used. For each 
serum sample, two replicates were run in parallel, and three experiments 
were performed. Results are expressed as mean percentage (±SD)  
of the OD observed at physiological (150 mM) NaCl concentration.  
P-values (****, P = 0.001) were determined by two-way ANOVA.
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et al., 2009; Cassani et al., 2010b). However, the possible 
contribution of defects in B cell tolerance to the immuno-
pathology of Omenn syndrome and leaky SCID has not been 
previously investigated. RAG-dependent immunodeficiency 
is characterized by profound B cell lymphopenia (Villa et al., 
2001), although residual production of antibodies (IgE in par-
ticular) and ability to mount low-affinity antibody responses to 
bacteriophage x174 neoantigen have been reported in pa-
tients with hypomorphic RAG mutations (Ochs et al., 1974). 
Importantly, autoimmune cytopenias have been observed in 
several patients with Omenn syndrome or with leaky SCID 
caused by hypomorphic RAG defects (Ehl et al., 2005; de 
Villartay et al., 2005), implying that B cell–mediated mecha-
nisms may contribute to the immunopathology of these dis-
eases, The recent availability of suitable animal models has 
made it possible to study in greater detail B cell development, 
maturation, and function in conditions associated with hypo-
morphic Rag mutations. The Rag1 S723C mutant protein is 
proficient for DNA cleavage but exhibits severe defects in 
elevated BAFF serum levels are frequently also observed among 
patients with hypomorphic RAG defects.
DISCUSSION
Immune dysregulation is increasingly being recognized as a 
prominent feature of genetically determined immunodefi-
ciencies (Carneiro-Sampaio and Coutinho, 2007; Liston et al., 
2008; Pessach et al., 2009). RAG mutations in humans may 
cause complete or partial defects of V(D)J recombination and, 
hence, result in SCID or in a leaky phenotype with residual 
T (and sometimes B) cell development associated with im-
mune dysregulation and skewing of the T lymphocyte reper-
toire (Signorini et al., 1999). We and others have previously 
shown that the reduced thymopoiesis in patients with Omenn 
syndrome and leaky SCID is accompanied by defects in thy-
mic epithelial cell maturation and/or homeostasis, impaired 
expression of aire (autoimmune regulator) protein and poor 
generation and function of CD4+ CD25+ Foxp3+ natural 
regulatory T cells (nT reg cells; Cavadini et al., 2005; Poliani 
Figure 5. Impaired receptor editing and increased serum BAFF 
levels in mut/mut mice. (A) Levels of V-RS DNA rearrangement prod-
ucts were measured by quantitative PCR in sorted bone marrow B220+ 
CD43 AA4.1+ IgM (Fraction D) cells from wild-type (+/+, n = 4) and 
mut/mut (n = 5) mice. Results were expressed as relative levels of V-RS 
DNA rearrangement products as compared with a reference value of 1 
attributed to DNA from sorted Fraction D bone marrow cells from one 
selected wild-type (+/+) mouse. Genomic DNA extracted from the tail of 
wild-type mice was run in parallel. For each of two experiments per-
formed, quantitative PCR was run in triplicates. Horizontal bars identify 
mean values. P-values (****, P < 0.001) were determined by a two-tailed 
Student’s t test for unpaired data. (B) Serum BAFF levels in 8-wk-old,  
16-wk-old, and 9–10-mo-old wild-type (+/+, n = 6–8) and mut/mut  
(n = 8–20) mice. Horizontal bars represent mean values. For each serum 
sample, three replicates were run and three experiments were performed. 
P-values (*, P < 0.05; **, P < 0.01; ****, P < 0.001) were determined by a 
two-tailed Student’s t test for unpaired data.
Figure 6. Serum BAFF levels in patients with RAG mutations.  
Serum BAFF levels in 19 patients with RAG mutations, 3 patients with  
T B SCID as a result of DCLRE1C (Artemis) deficiency, 12 patients with 
X-linked SCID (SCIDX1), and 11 age-matched controls. Different symbols 
identify distinct clinical phenotypes associated with RAG mutations as 
follows: , T B SCID; , Omenn syndrome; , leaky SCID; ◇, leaky 
SCID with granuloma. Horizontal bars represent mean value. For each 
serum sample, three replicates were run and three experiments were per-
formed. P-values (*, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001) 
were determined by a two-tailed Student’s t test for unpaired data.
Table I. Autoantibodies in patients with hypomorphic  
RAG mutations
Patients n n (%) with 
autoantibodies
Specificity
RAG deficiency
OS/LS 14 9 (64.3) Five ANA, four TPO, two 
pANCA, one TG, and one OmpC
T B SCID 5 0 (0)
SCIDX1 14 0 (0)
Controls 6 1 (16.7) ANA
OS, Omenn syndrome; LS, leaky SCID; TPO, thyroid peroxidase; pANCA, perinuclear 
anti-neutrophil cytoplasmic antibody; TG, thyroglobulin; and OmpC, outer 
membrane porin protein C.
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bodies that contain self-reactive specificities. Importantly, we 
have demonstrated for the first time that hypomorphic RAG 
mutations are associated with a high frequency of autoanti-
bodies also in humans. Our data indicate that several mecha-
nisms may be involved in generating and sustaining this 
B cell–mediated immune dysregulation. Normally, highly poly-
reactive and self-reactive B cells are counterselected at the 
primary B cell tolerance checkpoint in the bone marrow, 
mostly through receptor editing. It has been estimated that 
both in mice and in humans, 20–50% of developing B cells 
undergo receptor editing (Retter and Nemazee, 1998; Casellas 
et al., 2001; Wardemann et al., 2004). This process is accom-
panied by a drastic decrease in the proportion of self-reactive 
antibodies that are detected in early immature versus imma-
ture B lymphocytes in humans (Wardemann et al., 2003). 
A large fraction of autoantibodies expressed by these develop-
ing early immature B cells have low affinity for multiple anti-
gens (i.e., are polyreactive) and contain ANAs (Wardemann 
et al., 2003). Using a recently developed assay which is based on 
quantitation of RS rearrangement at the  locus (Panigrahi 
et al., 2008), we have demonstrated a drastic impairment of 
receptor editing in the bone marrow of mut/mut mice. Con-
sistent with this, we have also found that the proportion of 
peripheral B lymphocytes expressing  light chain is signifi-
cantly reduced in mut/mut mice and that anti-ssDNA anti-
bodies expressed , but not , light chains. Interestingly, we 
and others have recently reported increased levels of auto-
antibodies also in mice with hypomorphic mutations of DNA 
ligase IV (Nijnik et al., 2009; Rucci et al., 2010), another 
protein which is critically involved in T and B cell develop-
ment and receptor editing.
Our data suggest that disturbance in peripheral check-
points of B cell tolerance may also be involved in the patho-
physiology of autoimmunity associated with hypomorphic Rag 
mutations. BAFF serum levels were 10-fold higher in rag-
mutated mice and humans than in controls. Based on previous 
studies, this is likely the consequence of the B cell lymphope-
nic environment (Lesley et al., 2004; Lavie et al., 2007). High 
levels of BAFF-R are expressed by CD21int T2 B cells, which 
undergo extensive BAFF-mediated homeostatic proliferation 
(Meyer-Bahlburg et al., 2008). Anergic self-reactive B cells in 
the periphery express low levels of BAFF-R, show reduced 
BAFF responsiveness, and are normally lost at the T2 stage or 
beyond (Lesley et al., 2004; Thien et al., 2004). However, 
self-reactive peripheral B cells can be rescued by exogenous 
administration or overexpression of BAFF (Mackay et al., 1999; 
Lesley et al., 2004; Thien et al., 2004; Hondowicz et al., 
2007) and produce anti-chromatin and anti-DNA antibodies 
(Hondowicz et al., 2007). It has been shown that in vivo 
BAFF neutralization ameliorates islet-directed autoimmunity 
in nonobese diabetic mice by increasing competition among 
transitional B cells for follicular entry (Zekavat et al., 2008). 
We did not have access to BAFF-neutralizing antibody and, 
thus, could not directly test the significance of increased BAFF 
levels in the autoimmunity of mut/mut mice. In a companion 
paper, Cassani et al. (in this issue) report that i.v. injection of 
post-cleavage complex formation and end-joining (Tsai et al., 
2002; Giblin et al., 2009). Homozygosity for this mutation in 
mut/mut mice leads to a severe, although incomplete, block 
in B cell development but normal or even increased Ig levels. 
Similar observations had been previously reported in another 
model of leaky SCID, the MM mouse, with a homozygous 
Rag1 R972Q mutation (Khiong et al., 2007). Using ELISPOT 
assays, detailed flow cytometric analysis, and molecular assays 
to track terminal B cell maturation, we have now obtained 
substantial evidence that the spleens from mut/mut mice con-
tain an increased proportion of class-switched B cells and ISCs. 
Consistent with this, significant amounts of Igs of various 
isotypes are present in the serum of mut/mut mice. However, 
both the peripheral B cell repertoire and serum Ig profile 
from mut/mut mice show a restricted pattern. This likely re-
flects a limited number of productive V(D)J rearrangements 
as a result of the hypomorphic Rag1 mutation. The stochastic 
nature of the process may also account for some variability of 
serum Ig levels in mut/mut mice, as previously reported for 
IgE (Giblin et al., 2009). Several mechanisms may be taken 
into account to explain the apparent discrepancy between the 
B cell production bottleneck and significant Ig production in 
mut/mut mice. Adoptive bone marrow transfer experiments 
have shown that when limited numbers of B cells are trans-
ferred into immunodeficient mice, a large proportion of the 
transferred B cells undergo homeostatic proliferation and de-
velop into PCs (Agenès and Freitas, 1999; Cabatingan et al., 
2002). Furthermore, it has been demonstrated that under 
in vivo inflammatory conditions, immature/T1 B cells express 
significant levels of activation-induced cytidine deaminase and 
Blimp-1 (Ueda et al., 2007). In vitro activation of immature/
T1 B cells by toll-like receptor (TLR) ligands induces these 
cells to proliferate and secrete Igs in a TI manner (He et al., 
2004). Moreover, innate immune cells are over-reactive in 
lymphopenic environment (Cao et al., 2009), and this may 
lead to increased expression of cytokines (such as BAFF) that 
may favor B cell survival and/or differentiation (Ueda et al., 
2007). It can be speculated that the profound immunodefi-
ciency and defects in the gut-blood barrier may render mut/mut 
mice and patients with Omenn syndrome susceptible to in-
flammation sustained by endogenous commensal flora, as 
shown in other human immunodeficiencies (Brenchley et al., 
2006). Interestingly, 4% of mut/mut mice have developed colitis 
and/or erythroderma, and their spleens demonstrated very high 
numbers of ISCs.
We have demonstrated that mut/mut mice are severely 
impaired in the antibody response to TI and TD antigens, 
and in particular are unable to mount high-affinity antibody 
responses. Adoptive transfer of wild-type CD4+ T lympho-
cytes was unable to correct defective antibody response to 
TNP-KLH, indicating that B cell–intrinsic abnormalities (in-
cluding restricted B cell repertoire) and/or aberrant architec-
ture of secondary lymphoid organs (characterized by lack of 
follicles and of germinal centers) account for the impaired 
antibody response to TD antigens in mut/mut mice. However, 
they spontaneously produce high levels of low-affinity anti-
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loss, proteinuria, or reduced life span, under SPF conditions, 
and only a minority (4%) of them developed alopecia or colitis. 
In contrast, a significant proportion of Rag2R229Q mice develop 
features of Omenn syndrome by 8–10 wk of age (Marrella et al., 
2007). Furthermore, >10% of Rag2R229Q mice produce high-
affinity anti–double-stranded DNA antibodies and show 
prominent T and B cell infiltrates in the kidney (leading to 
proteinuria), the gut, and the skin, as reported by Cassani 
et al. (2010a) in the companion paper. Several mechanisms 
may account for the phenotypic heterogeneity both between 
and within these Rag-mutated mouse models. It is possible 
that the distinct Rag mutations carried by these models exert 
a different effect on the efficiency of V(D)J recombination, 
generation of T and B lymphocytes, and receptor editing and 
that the stochastic nature of the process contributes to the 
heterogeneity of the phenotype, even within the same model. 
Moreover, it is possible that differences in housing conditions 
and in the microbial gut flora may modulate B cell–mediated 
autoimmunity through TLR-mediated signaling. Consistent 
with this, Cassani et al. (2010a) have shown that B lympho-
cytes from Rag2R229Q mice respond efficiently to TLR ago-
nists undergoing terminal differentiation, Ig production, and 
class switch recombination. Finally, T lymphocytes may also 
play a role in precipitating the disease phenotype. In this regard, 
Cassani et al. (2010a) have shown that depletion of CD4+ 
T cells in Rag2R229Q mice leads to reduction of ISCs and nor-
malization of serum IgE, associated with a decrease of IL-21 
and IFN- serum levels. These factors may contribute to the 
significant variability of the clinical phenotype that has also 
been observed in patients with hypomorphic RAG muta-
tions, even within the same family (Villa et al., 2001).
In conclusion, we have established that hypomorphic 
RAG mutations in mice and humans are associated with 
autoantibody production. We have determined that this 
B cell–mediated immune dysregulation reflects profound 
abnormalities in the mechanisms that govern central and 
peripheral B cell tolerance. Experiments based on adoptive 
transfer of T reg cells, in vivo injection of TLR agonists, and 
generation of mut/mut mice carrying additional defects in 
TLR signaling may permit to define the relative contribution 
of impaired T cell–mediated control of B cell immune dysre-
activity and TLR-mediated B cell activation to the autoim-
mune phenomena of leaky SCID and Omenn syndrome.
MATERIALS AND METHODS
Mouse strains. 129Sv Rag1S723C (mut/mut) mice were previously generated and 
described (Giblin et al., 2009). Zap70/ mice (Negishi et al., 1995), backcrossed 
to C57BL/6 background, were a gift from A. Singer (National Cancer Institute, 
Bethesda, MD). 129Sv and C57BL/6 wild-type (+/+) mice were purchased 
from Charles River. Aicda/ mice were previously described (Muramatsu et al., 
2000) and were a gift from T. Honjo (Kyoto University, Kyoto, Japan). Mice 
were housed at the Karp Family Research Building under specific pathogen-free 
conditions. Animal studies were approved by the Animal Care and Use Commit-
tee, Children’s Hospital Boston (protocol 07–10-1445).
Patients. Sera were obtained at diagnosis, before treatment, from a total of 
19 patients with molecularly confirmed RAG-dependent immunodeficiency 
(14 patients with SCIDX1, 3 patients with DCLRE1C (Artemis) deficiency, 
an anti–BAFF-R monoclonal antibody into Rag2R229Q mice 
led to disappearance of anti–double-stranded DNA IgG anti-
bodies and significant amelioration of inflammatory infiltrates. 
In contrast, BAFF-R–deficient A/WySnJ mice develop auto-
antibodies and severe glomerulonephritis (Mayne et al., 2008), 
indicating that balance of BAFF levels may be important to 
maintain B cell tolerance. Consistent with this, we found that 
increase of mature B cell number in older mut/mut mice was 
associated with decrease of BAFF serum levels and normal-
ization of the titer of anti-ssDNA and anti-chromatin anti-
bodies. Altogether, these data suggest that increased BAFF 
serum levels play a significant role in autoimmune manifesta-
tions associated with hypomorphic Rag mutations.
There is supporting evidence that elevated BAFF serum 
levels may also associate with immune dysregulation in humans 
(Moisini and Davidson, 2009). Very elevated serum BAFF 
concentrations were detected in our series of 19 patients with 
RAG mutations, including 14 patients with Omenn syndrome 
or leaky SCID, 9 of which had evidence of autoantibodies. 
Levels of BAFF were higher in patients with RAG mutations 
than in those with SCIDX1, none of which developed signs 
of autoimmunity. It is possible that a certain threshold of 
BAFF concentration must be reached to rescue self-reactive B 
cells in the periphery. However, other non–mutually exclu-
sive mechanisms may also account for the different incidence 
of autoimmunity between patients with hypomorphic RAG 
defects and those with SCIDX1. Impaired receptor editing is 
anticipated in RAG deficiency but not in SCIDX1. Further-
more, patients with SCIDX1 typically lack mature T lympho-
cytes, whereas both in humans and in mice hypomorphic 
RAG mutations are often associated with a variable number of 
oligoclonal and in vivo activated T cells that infiltrate target 
organs and may promote and/or sustain B cell–mediated auto-
immunity. In the companion manuscript, Cassani et al. (2010a) 
show that in vivo depletion of CD4+ cells in Rag2R229Q 
mice results in the decrease of ISCs and normalization of 
serum IgE. In contrast, autoimmunity develops to the same 
extent in both T cell–sufficient and in T cell–deficient BAFF-
transgenic mice (Groom et al., 2002), indicating that BAFF-
mediated rescue of self-reactive B cells may be T cell 
independent. In this regard, it is noteworthy that adoptive 
transfer of wild-type CD4+ T cells did not ameliorate auto-
immunity in mut/mut mice. Nonetheless, it is likely that the 
severe defects in T cell development and function observed in 
mut/mut mice and in patients with Omenn syndrome and leaky 
SCID may contribute to B cell–mediated immune dysregula-
tion. In particular, we and others have shown that hypo-
morphic RAG mutations are associated with a severe defect in 
the ability to support nT reg cells development and function 
both in mice (Marrella et al., 2007) and in humans (Poliani et al., 
2009; Cassani et al., 2010b).
We have shown that mut/mut mice produce polyreactive 
low-affinity antibodies with self-reactive specificities. Usually, 
such antibodies are not associated with organ-specific auto-
immunity and tissue damage. Consistent with this, mut/mut 
mice did not show significant signs of disease, such as weight 
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I-C1 post-switch transcript and Xbp1 transcript were amplified using 
cDNA prepared from B cell–enriched (CD90 negative) splenocytes as a 
template. mb-1 transcripts were used as internal control. Primers used for 
I-C1 post-switch transcript were previously described (Muramatsu et al., 
2000). The following primers were used to amplify mb-1 and Xbp1 tran-
scripts: mb-1 forward, 5-GCCAGGGGGTCTAGAAGC-3; mb-1 
reverse, 5-TCACTTGGCACCCAGTACAA-3; Xbp1 forward, 5-TAG-
AAAGAAAGCCCGGATGAGCGA-3; and Xbp1 reverse, 5-TGACAG-
GGTCCAACTTGTCCAGAA -3.
Immunoscope profiling of BCR. The diversity of splenic B cell reper-
toire was analyzed in +/+ and mut/mut mice (n = 4 for both) by immuno-
scope analysis. In brief, cDNA was prepared from B cell–enriched spleno-
cytes obtained by negative selection using the CD90.2 kit. The CDR3 re-
gion of Ig heavy chain variable (V) region was amplified using a V-specific 
forward primer and a common reverse primer in the JH region (5-CTT-
ACCTGAGGAGACGGTGA-3; Carey et al., 2008). Forward primers 
were the following: MIGHV1, 5-TCCAGCACAGCCTACATGCAG-
CTC-3; MIGHV2, 5-CAGGTGCAGCTGAAGGAGTCAGG-3; 
MIGHV3, 5-AGGTGCAGCTTCAGGAGTCAGG-3; MIGHV5, 5-
CAGCTGGTGGAGTCTGGGGGA-3; MIGHV6, 5-AAGTGAAGC-
TTGAGGAGTCTGG-3; and MIGHV7, 5-AGGTGAAGCTGGTG-
GAGTCTGG-3.
Amplification reactions were performed using 2 ng cDNA in 50 µl of 
reaction containing 1 U/µl Taq Gold DNA polymerase, 200 µM dNTPs, 1 µM 
of each primer, and 1.5 mM MgCl2 in 10× amplification buffer (Applied 
Biosystems). After 10 min at 95°C, amplification was performed for 40 
cycles as follows: 30 s at 94°C, 30 s at 60°C, 1 min 30 s at 72°C, and ended 
with a step of 10 min at 72°C. Each PCR product was subjected to four 
runoff cycles primed with the same primer used as reverse for the PCR reac-
tion labeled with 0.2 µM FAM in the presence of 1 U/µl Taq Gold DNA 
polymerase, 200 µM dNTPs, and 1.5 mM MgCl2 in 10× amplification buf-
fer. Runoff cycles are as follows: 2 min at 94°C, 2 min at 60°C, and 20 min 
at 72°C. PCR products were then processed on an ABI3130 Genetic ana-
lyzer (Applied Biosystems). Spectratype data were analized using GeneMap-
per v3.7 software (Applied Biosystems).
Analysis of receptor editing by RS rearrangement. Quantitative PCR 
for VK-RS rearrangement was performed as previously described (Panigrahi 
et al., 2008) with slight modifications, using a protocol provided by S. Koralov 
(Harvard University, Boston MA). In brief, bone marrow cells from 12-wk-
old +/+ (n = 4) and mut/mut (n = 5) mice were incubated with B220-APC, 
AA4.1-PECy7, IgM-PE, and CD43 FITC antibodies, and Fraction D 
(B220+ AA4.1+ IgM CD43) cells were sorted on a FACSAria (BD). Purity of 
the sorted population was consistently >97%. Genomic DNA was extracted 
from sorted Fraction D bone marrow cells using the Gentra Puregene Tissue 
kit (QIAGEN). Germline DNA isolated from the tail of four +/+ mice served 
as a negative control. For quantitative PCR, Power SyBR Green PCR Master 
Mix (Applied Biosystems) was combined with 10 ng of template DNA in a 
20-µl reaction mix containing 20 pMol of forward primer (5-AGC-
TTCAGTGGCAGTGGRTCWGGRAC-3) and 20 pMol of reverse 
primer (5-ACATGGAAGTTTTCCTGGGAGAATATG-3). 40 cycles of 
amplification were run (95°C for 10 min, 95°C for 15 s, and 60°C for 1 min) 
and analyzed on an AB 7500 real-time PCR system (Applied Biosystems) 
using standard quantitative PCR protocol. Amplification of GADPH was 
run in parallel as a calibrator. The amount of VK-RS product in each mouse 
sample was normalized to the amount of GAPDH and compared with the 
normalized target value in sorted Fraction D cells from +/+ mice (compara-
tive CT[CT] method). Statistical analysis was performed using Student’s 
t test for unpaired data.
Immunization with TNP-Ficoll and TNP-KLH. To elicit TI antibody 
responses, gender-matched 8-wk-old mut/mut and +/+ mice were injected 
i.p. with 50 µg TNP-Ficoll (Biosearch Technologies). Sera were collected at 
the time of immunization (t0) and 14 d later (t14), and anti-TNP IgM and 
and 11 age-matched controls) upon informed consent by the local Institution 
Review Board (IRB) and in respect to the Helsinki declaration. Human studies 
were approved by Children’s Hospital Boston IRB, protocol 04–09-113R).
Antibodies, flow cytometry, and immunohistochemistry. For flow 
cytometry, the following anti–mouse antibodies were used: B220-FITC, 
CD21-FITC, IgM-APC, CD38-PE, Fas-PE-Cy7, CD11b-biotin, Gr-1-
biotin (BD), B220–Alexa Fluor 700, AAA4.1-PE, CD23-PE-Cy7, IgD–
Pacific Blue, IgM-PE-Cy5, GL7-APC, CD11c-biotin (eBioscience), and 
IgG1/2a-FITC (BioLegend). For biotinylated antibodies, streptavidin-PerCP 
was used in the secondary step. Data were acquired on a FACSCalibur cytom-
eter (BD) and LSR flow cytometer (BD) and analyzed using FlowJo (version 
8.2 for Mac; Tree Star, Inc.).
For characterization of the splenic B cell compartment, 5-µm sections of 
the spleens from 8-wk-old mut/mut and +/+ mice (n = 4 for each) were in-
cubated with B220–Alexa Fluor 647, IgG–Alexa Fluor 488, IgG2a-PE 
(Invitrogen), and peanut agglutinin–FITC (Vector Laboratories). To detect 
immune complexes in the kidney glomeruli, 5-µm frozen sections were pre-
pared from the kidneys of four 12-wk-old mut/mut, two 12-wk-old +/+, 
three 8-mo-old mut/mut, and two 8-mo-old +/+ mice. Glomerular immune 
complexes were revealed using Alexa Fluor 488–labeled anti–mouse IgM 
and C3 (Invitrogen). Images were acquired using a Radiance 2000MP con-
focal imaging system (Bio-Rad Laboratories) using 20 and 40× objectives 
controlled by LaserSharp software (Bio-Rad laboratories).
Immunohistochemistry of peripheral organs was performed on a total of 
45 mut/mut and 10 +/+ mice ranging from 8 wk to 11 mo of age. 4-µm-
thick sections from formalin-fixed paraffin-embedded tissue samples were 
stained with hematoxylin and eosin and immunostained as previously de-
scribed (Poliani et al., 2009). The following primary antibodies were used: 
rat anti-B220 (clone RA3-6B2, 1:100; Invitrogen), rabbit anti-CD3 (1:100; 
Dako), and rabbit anti–Iba-1 (1:500; Wako Chemicals USA, Inc.). PCs were 
detected directly by using either an appropriate biotinylated goat anti–mouse 
IgM antibody (Vector Laboratories) or ChemMate Envision Mouse-HRP 
kit (Dako) that binds specifically to the mouse Ig. Digital images were ac-
quired with a camera (DP70; Olympus) using AnalySIS software (Olympus). 
The degree of inflammation was scored using the following criteria: 0, 
none/scarce; 1, low; 2, moderate; 3, high. Colitis was graded as previously 
described (Scheiffele and Fuss, 2002).
To detect tissue-specific antibodies in the serum of mut/mut mice, 5-µm 
cryostat tissues from various organs (skin, stomach, small and large bowel, 
kidney, salivary glands, muscles, pancreas, and ovaries) of rag2/ mice were 
fixed in ice-cold acetone and were incubated with 1:100 and 1:400 dilutions 
of serum from mut/mut (n = 11) or +/+ (n = 6) mice. Reactions were re-
vealed with Alexa Fluor 488–labeled F(ab)2 anti–mouse IgG secondary anti-
body (Invitrogen). Slides were viewed with a microscope (Laborlux D; Leitz) 
using 20 and 40× Plan Neofluar objectives (Carl Zeiss, Inc.). Images were 
acquired with a camera (DFC 300F; Leica) and processed with FireCam 
software (Leica).
Analysis of ISCs by ELISPOT. Multiscreen HA plates (Millipore) were 
coated with 5 µg/ml of anti–mouse  and anti–mouse  antibodies (Southern-
Biotech). Splenocytes from 12-wk-old mut/mut, +/+, and aicda/ mice 
were enriched for B cells by negative selection using EasySep (STEMCELL 
Technologies Inc.), according to the manufacturer’s instructions. Cells were 
plated in twofold dilutions starting from several groups of 105 cells. After 
overnight incubation at 37°C in 5% CO2, the plates were washed, and IgM-, 
IgG1-, IgG2a-, and IgA-ISCs were detected by incubating with anti–mouse 
isotype-specific biotinylated antibodies (SouthernBiotech), followed by incu-
bation with streptavidin–horseradish peroxidase (HRP) and 3-amino-9-
ethylcarbazole (Sigma-Aldrich) as chromogen. Spots were counted by an 
Elispot Reader (Cellular Technology Ltd.) using a size range of 0.005–1 mm.
Analysis of post-switch transcripts and Xbp1 expression. Spleno-
cytes of 8-wk-old +/+ (n = 3) and mut/mut (n = 3) mice were enriched 
for B cells by negative selection using the CD90.2 kit (Miltenyi Biotec). 
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Determination of BAFF serum levels by ELISA. Evaluation of BAFF 
levels in mouse serum was performed by ELISA using a kit (R&D Systems) 
according to the manufacturer’s instructions. Concentrations of BAFF in 
human sera were tested by ELISA as previously described (Lindh et al., 
2008). Statistical analysis was performed using a two-tailed Student’s t test.
Autoantibody detection. Levels of anti-ssDNA antibodies in mouse sera 
were assessed by ELISA, as previously described (Zouali and Stollar, 1986), with 
some modifications. In brief, Immulon (Dynatech Laboratories) plates were 
UV irradiated and then coated with 2.5 µg/ml ssDNA (Sigma-Aldrich). 
Samples were incubated on plates in 1:400 dilution, and then plates were 
washed and bound autoantibodies were detected with anti–mouse IgG- HRP 
(GE Healthcare), followed by incubation with TMB and reading at 450 nm. 
Levels of anti-ssDNA antibodies were expressed as ELISA units, using a 
standard curve prepared with serial dilutions of ANA-positive NZM2410 
serum pool. For detection of light chain isotype of anti-ssDNA antibodies, 
final incubation was with anti–mouse  or anti–mouse- AP antibody 
(SouthernBiotech), followed by reaction with p-NP and reading of OD at 
405 nm. Results were expressed as the OD ratio (experimental OD/back-
ground OD).
Levels of anti-chromatin (anti-histone–DNA complex) antibodies in 
mouse sera were determined by ELISA as previously described (Mohan 
et al., 1998) and expressed as ELISA units, using a standard curve prepared 
with serial dilutions of ANA-positive NZM2410 serum pool, or expressed as 
OD ratio. For both anti-ssDNA and anti-chromatin antibodies, statistical 
analysis was performed using the Mann-Whitney U test.
For immunohistochemistry, Hep-2 cell–coated slides (Antibodies In-
corporated) were incubated at room temperature with serum samples from 
mut/mut or +/+ mice at a 1:160 dilution, followed by incubation with Alexa 
Fluor 488 anti–mouse IgG F(ab)2 antibody (Invitrogen). Reactions were 
visualized by fluorescence microscopy. Background was adjusted with nega-
tive control samples. Slides were viewed with a microscope (Eclipse 90i; 
Nikon) using Plan Fluor 20× and Plan Apo 40x objectives (Nikon). Images 
were acquired using a camera (Orca-ER; Hamamatsu Photonics) and were 
processed with MetaMorph imaging software (version7.1.2.0; MDS Analytical 
Technologies). Statistical analysis was performed using the 2 test.
Affinity of serum anti-ssDNA antibodies was assessed in mut/mut (n = 8) 
and in NZM2410 (n = 7) mice by ELISA using increasing NaCl concentra-
tion. ELISA plates were prepared as previously described (Zouali and Stollar, 
1986). Serum samples, diluted 1:400, were incubated at four different NaCl 
concentrations (150, 300, 600, and 1,200 mM). Plates were washed, and 
bound autoantibodies were detected with anti–mouse IgG-HRP (GE 
Healthcare), followed by incubation with TMB and reading at 450 nm. 
Levels of anti-ssDNA antibodies were expressed as percentage of OD com-
pared with the ODmax, detected at physiological (150 mM NaCl) salt 
concentration. Statistical analysis was performed using two-way ANOVA.
Clinical data regarding tissue-specific autoantibodies from human sub-
jects were obtained from collaborating sites. Human IgG/A/M ANAs were 
detected by immunohistochemistry, using slides coated with Hep-2 cells and 
cryostat tissues of rat kidney, liver, and stomach (Mosaik Basisprofil; Euro-
immun), which were incubated at room temperature with patients’ serum 
samples at 1:40 and 1:160 dilutions, followed by incubation with FITC–
labeled anti-IgG/A/M conjugate (Euroimmun). Four samples from patients 
with RAG mutations that tested positive for ANA at a titer ≥1:80 were ana-
lyzed for ANA isotype, using FITC-conjugated anti–human IgG (BD) or 
FITC-conjugated anti–human IgM (BD). The reaction was visualized by 
fluorescence microscopy. Background was adjusted with negative control 
samples. Slides were viewed with a Leica DLMB microscope using HC PL 
Fluotar 20×/0.5 NA and HCX PL Fluotar 40×/0.75 NA objectives (Leica). 
Images were acquired using a camera (DFC 420C; Leica) and processed with 
Application Suite 3.4.0 imaging software (Leica). Statistical analysis was per-
formed using the 2 test.
Online supplemental material. Fig. S1 shows oligoclonal repertoire of 
splenic B cells in mut/mut mice. Fig. S2 illustrates lack of germinal centers, and 
IgG3 antibody titers were measured by ELISA as previously described 
(Tsitsikov et al., 1997), using alkaline phosphatase (AP)–conjugated goat 
anti–mouse IgM and IgG3, followed by reaction with p-nitrophenylphos-
phate (Sigma-Aldrich). The serum samples were run with six fivefold dilu-
tions for determination of end-titer dilution. For TD antigen responses, 
gender-matched 8-wk-old mut/mut and +/+ mice were injected i.p. with 
100 µg TNP-KLH (Biosearch Technologies) and aluminum adjuvant 
(Thermo Fisher Scientific) at the time of the first immunization and with 
25 µg TNP-KLH for secondary immunization, 2 wk apart. Sera were collected 
on the day of the primary immunization (t0), at the time of the secondary 
immunization (t14), and 1 wk later (t21) and IgM, total, and high-affinity anti-
TNP IgG antibody titers were measured by ELISA using high binding Co-
star EIA plate (Corning). To distinguish between total and high-affinity 
TNP-specific IgG responses, plates were coated with TNP(18)-BSA and 
TNP(3)-BSA, respectively. TNP-specific IgM were detected using AP-
conjugated goat anti–mouse IgM, followed by reaction with p-nitrophenyl-
phosphate (p-NP; Sigma-Aldrich) and reading of OD at 405 nm. To detect 
total and high-affinity TNP-specific IgG responses, HRP-conjugated sheep 
anti–mouse IgG (GE Healthcare) was used, and the reaction was revealed 
with 3,3,5,5 tetramethylbenzidine (TMB; BD), followed by OD reading at 
450 nm. Serum samples were run with six fivefold dilutions for end-titer 
determination. Statistical analysis was done using two-way ANOVA.
Adoptive CD4+ T cell transfer. CD4+ splenic T cells from +/+ or 
mut/mut mice were enriched by negative selection using the CD4+ T cell 
isolation kit (Miltenyi Biotec). A total of 3 × 106 CD4+ +/+ or mut/mut 
T cells were adoptively transferred into mut/mut mice (n = 5 per group). 
In parallel, 3 × 106 CD4+ T cells from syngeneic wild-type mice were 
adoptively transferred into zap70/ mice (n = 5). Control groups included 
+/+ mice and zap70/ mice (n = 5 per group) that did not receive CD4+ 
T cell transfer. 1 d after the adoptive transfer, all mice were immunized 
i.p. with TNP-KLH as described in the previous section, followed by a 
boosting immunization 2 wk later. Sera were collected at the time of pri-
mary immunization (t0), 7 d after secondary immunization (t21), and 54 d 
after adoptive transfer.
Determination of serum Igs by ELISA. Nunc Immuno plates (Thermo 
Fisher Scientific) were coated with 2.5 µg/ml of unlabeled goat anti–mouse 
IgM, IgG1, IgG2a, IgG2b, IgG3, IgA (SouthernBiotech), and IgE (BD). 
Samples were incubated on plates in a dilution ranging from 1:1,000 to 
1:10,000 for IgM, 1:5,000 to 1:10,000 for IgG1 and IgG2b, 1:1,000-1:2,000 
for IgG2a, 1:2,000 to 1:5,000 for IgG3, and 1:50 and 1:100 for IgE. Plates 
were washed and bound autoantibodies were detected with corresponding 
AP-conjugated goat anti–mouse IgM, IgG1, IgG2a IgG2b, IgG3 (all from 
BD), and IgA (SouthernBiotech) antibodies. For IgE determination, a bio-
tinylated anti-IgE (BD) primary antibody was used, followed by streptavi-
din-HRP. Colorimetric reaction was produced by final incubation with 
p-nitrophenylphosphate (Sigma-Aldrich) for IgM, IgG1, IgG2a, IgG2b, 
IgG3, and IgA and ABTS Peroxidase substrate (KPL) for IgE. OD was mea-
sured at 405 nm and 450 nm for AP- and HRP-mediated reactions, respec-
tively, using an ELISA reader (BioTek Instruments). A standard curve, using 
a serum with known concentrations of Igs, was run in parallel. Statistical 
analysis was performed using a two-way Student’s t test.
Serum electrophoresis and immunofixation. Electrophoresis and 
immunofixation of human sera (RAG-mutated Omenn syndrome, n = 4; 
multiple myeloma, n = 1; systemic lupus erythematosus, n = 1; healthy con-
trol, n = 1) was performed according to the manufacturers instructions 
(HYDRASYS; Sebia, Inc.). Adjustments for mouse serum immunofixation 
were as follows: 20 µl of mouse serum and 15 µl of diluent (Sebia, Inc.) were 
mixed and 10 µl was loaded per lane (three lanes: protein electrophoresis/
IgG/IgM). Donkey anti–mouse IgM and donkey anti–mouse IgG (Jackson 
ImmunoResearch Laboratories, Inc.) were diluted 1:5 in 0.9% NaCl. Theel 
was fixed using 38 µl ELP fixative (lane 1) or 24 µl of diluted anti–mouse 
IgG or anti–mouse IgM.
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